Tumour angiogenesis: Pathophysiology and clinical significance

Netherlands Journal of Medicine

Volumn 49, Issue 1, 1996, Pages 42-51

  Lichtenbeld, H H C ^a   Van Dam Mieras, M C E ^b   Hillen, H F P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

Author keywords

Antiangiogenesis; Endothelial cell; Growth factors; Haemostasis; Inflammatory cell; Stroma; Tumour angiogenesis

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEINASE INHIBITOR; SOMATOSTATIN; STEROID; SUBSTANCE P; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CANCER INHIBITION; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; INFLAMMATORY CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; REVIEW; STROMA CELL; TUMOR BLOOD FLOW;

EID: 0030198185     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(95)00117-4     Document Type: Review

References (126)

1. [1] Goldmann E. Growth of the malignant disease in man and the lower animals with special reference to the vascular system. Proc R Soc Med 1907;1:1.
2. [2] Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. [3] Ingber D, Fujita T, Kishomoto S, et al. Angioinhibins: synthetic analogues of fumagillin which inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
4. [4] Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial cell growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844.
5. [5] Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 1992;667:101-111.
6. [6] Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol 1991;138:1437-1450.
7. [7] Dvorak HF. Tumors, wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
8. [8] Ezekowitz RAB, Mulliken JB, Folkman J. Interferon α-2a therapy for life-threating hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
9. [9] Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogensis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-298.
10. [10] Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
11. [11] Folkman J. Angiogenesis in cancer, vasculature, rheumatoid and other disease. Nature Med 1995;1:27-30.
12. [12] Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
13. [13] Liotta L, Steeg PS, Stetler-Stevensen WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
14. [14] Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
15. [15] Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-2658.
16. [16] Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumours. Br J Cancer 1982;46:711-720.
17. [17] Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
18. [18] Aznavoorian S, Stetler-Stevenson W, Murphy A, Liotta L. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
19. [19] Bernstein L, Liotta L. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 1994;6:106-113.
20. [20] Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE. Tumor invasion, proteolysis, and angiogenesis. J Neurooncol 1995;18:89-103.
21. [21] Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Science 1991;251:1451-1455.
22. [22] Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
23. [23] Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993;4:219-229.
24. [24] Fidler IJ, Ellis LM. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
25. [25] Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-848.
26. [26] Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J. Vlodavsky I. Basic fibriblast growth factor binds to sub-endothelial matrix and is released by heparatinase and heparin-like molecules. Biochemistry 1989;28:1737-1743.
27. [27] Maciag T, Schrieber A, Mehlman T, Friesel R. Heparin binds endothelial cell growth factor, the principal mitogen in bovine brain. Science 1984;225:932-935.
28. [28] Gospodarowicz D, Cheng J, Lui G, Baird A, Bohlen P. Isolation of brain fibroblast growth factor by heparin-sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci USA 1984;81:8963-8967.
29. [29] Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1989;1:207-235.
30. [30] Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: Models and modulators. Int Rev Cytol 1995;159:113-160.
31. [31] Senger DR, Van De Water L, Brown LF, et al. Vascular permeability factor (VPF/VEGF) in tumor biology. Cancer Metast Rev 1993;12:303-324.
32. [32] Berse B, Brown LF, Van De Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial cell growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol Biol Cell 1992;3:211-220.
33. [33] Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
34. [34] Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, and endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
35. [35] Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial cell growth factor and its receptor fit and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-516.
36. [36] Warren RS, Yuan H, Matli MR, Gilllett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
37. [37] Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995;55:1189-1193.
38. [38] Ferrara N, Houck K, Jakema L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinology 1992;13:18-32.
39. [39] Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-1478.
40. [40] Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-a in angiogenesis. Am J Pathol 1992;140:539-544.
41. [41] Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986;320:584-588.
42. [42] Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-a. Nature 1987;329:630-632.
43. [43] Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-248.
44. [44] Cozzoli F, Torcia M, Aldinucci D, et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA 1990;87:6487-6491.
45. [45] Gay CG, Winkles JA. Interleukin-1 regulates heparin-binding growth factor-2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1991;88:296-300.
46. [46] Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M. Human endothelial cells produce IL-6: Lack of response to exogenous IL-6. Ann NY Acad Sci 1989;557:374-385.
47. [47] Van Snick J. Interleukin 6: an overview. Annu Rev Immunol 1990;8:253-278.
48. [48] Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage derived mediator of angiogenesis. Science 1992;258:1799-1801.
49. [49] Hu DEK, Hory Y, Fan T. Interleukin 8 stimulates angiogenesis in rats. Inflammation 1993;17:135-143.
50. [50] Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1988;948:305-326.
51. [51] Van Meir EG, Polverini P, Chazin VR, Su Hang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994;8:171-176.
52. [52] Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327.
53. [53] Falanga A, Gordon S. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558-5567.
54. [54] Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-805.
55. [55] Lichtenbeld HHC, Muller AD, van Dam-Mieras MCE, Blijham GH. Tumor spheroid-induced vesicle formation on endothelial cells is associated with procoagulant properties. J Cell Sci 1993;106:657-662.
56. [56] Nakanishi H, Oguri K, Takenaga K, Hosoda S, Okayama M. Differential fibrotic stromal responses of host tissue to low- and high metastatic cloned Lewis lung carcinoma cells. Lab Invest 1994;70:324-332.
57. [57] Antonelli Orlidge A, Saunders KB, Smith SR, D'Amore PA. Activated form of transforming growth factor-beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989;86:4544-4548.
58. [58] Schlingemann RO, Rietveld FLR, Kwaspen F, van de Kerkhof PCM, de Waal RMW, Ruiter DJ. Differential expression of markers for endothelial cells, pericytes and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 1991;138:1335-1347.
59. [59] Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992;3:73-79.
60. [60] Reed JA, Albino AP, McNutt NS. Human cutaneous mast cells express basic fibroblast growth factor. Lab Invest 1995;72:215-222.
61. [61] Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukocyte Biol 1994;55:410-422.
62. [62] Gullino P. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol 1995;34:439-441.
63. [63] Roche WR. The nature and significance of tumour-associated mast cells. J Pathol 1986;48:175-182.
64. [64] Starkey JR, Crowle PK, Taubenberger S. Mast-cell deficient w/wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988;42:48-52.
65. [65] Muller AD, Lichtenbeld HC, Vossen R, Van Dam-Mieras MCE, Blijham GH. Mast cells induce a procoagulant response on endothelial cells. Thromb Res 1993;72:263-267.
66. [66] Szatrowski T, Nathan C. Production of large amounts of hydrogen peroxides by human tumor cells. Cancer Res 1991;51:794-798.
67. [67] Lichtenbeld HHC, Muller AD, Vossen RCRM, Blijham GH, Van Dam-Mieras MCE. Lipid peroxidation of cells:a possible mechanism in tumor angiogensis? In: Tumor angiogenesis: an in vitro study. Maastricht: Datawyse University Press, Maastricht, 1993;59-70.
68. [68] Murray JC, Clauss M, Denekamp J, Stern D. Selective induction of endothelial cell tissue factor in the presence of a tumour derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature. Int J Cancer 1991;49:254-259.
69. [69] Van Deijk WA. Studies on the influence of cancer and hormonal cancer treatment on haemostatic parameters. Maastricht: University of Maastricht, 1986;120.
70. [70] Van Wersch JW, Peters C, Ubachs JM. Coagulation factor XIII. Eur J Clin Biochem 1994;32:681-684.
71. [71] Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975;6:127.
72. [72] Gordon SG. Cancer procoagulant. In: Muszbek L, ed. Cancer procoagulant. Boca Raton, FL: CRC Press Inc., 1987:
73. [73] Dameron K, Volpert O, Tainsky M, Bouck N. Control of angiogenesis in fibroblasts by p. 53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
74. [74] Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993;1182:1-14.
75. [75] Weinstat Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-6511.
76. [76] Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995;92:6788-6792.
77. [77] Dameron KM, Volpert OV, Tainsky MA, Bouck N. The p. 53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994;59:483-489.
78. [78] Boukerche H, Berthiervergnes O, Tabone E, Bailly M, Dore JF, McGregor JL. Thrombospondin modulates melanoma-platelet interactions and melanoma tumour cell growth in vivo. Br J Cancer 1995;72:108-116.
79. [79] Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
80. [80] Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995;130:503-506.
81. [81] Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
82. [82] Gasparini G, Harris A. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-782.
83. [83] Axelsson K, Ljung BE, Moore II DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995;87:997-1008.
84. [84] Brem H, Gresse I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993;28:1253-1257.
85. [85] Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
86. [86] Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995;72:257-267.
87. [87] Folkman J, Ingber DE. Angiostatic steroid. In: Schleimer CO, ed. Angiostatic steroid. New York: Academic Press, 1989;330-350.
88. [88] Sipos EP, Tamargo RJ, Weingart JD, Brem H. Inhibition of tumor angiogenesis. Ann NY Acad Sci 1994;732:263-272.
89. [89] Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
90. [90] Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
91. [91] Jain RK. Physiological resistance to the treatment of solid tumors. In: Teicher BE, ed. Physiological resistance to the treatment of solid tumors. New York: Marcel Dekker, 1993;87-105.
92. [92] Jain RK. Transport of molecules across tumor vasculature. Cancer Metast Rev 1987;6:559-593.
93. [93] Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-5114.
94. [94] Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-3356.
95. [95] Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-6560.
96. [96] Chester KA, Hawkins RE. Clinical issues in antibody design. Trends Biotechnol 1995;13:294-300.
97. [97] Imanishi K, Yamaguchi K, Suzuki M, Honda S, Yanaihara N, Abe K. Production of transforming growth factor-a in human tumour cell lines. Br J Cancer 1989;59:761-765.
98. [98] Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-a: a more potent angiogenic mediator than epidermal growth factor. Science 1986;232:1250-1253.
99. [99] Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987;84:6020-6024.
100. [100] Yang EY, Moses HL. Transforming growth factor beta-1 induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111:731-741.
101. [101] Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991;87:986-995.
102. [102] Martinet Y, Bitterman PB, Mornex JF, Grotendorst GR, Martin GR, Crystal RG. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature 1986;319:158-160.
103. [103] Raines EW, Ross R. Platelet-derived growth factor in vivo. In: Sorg BWC, ed. Platelet-derived growth factor in vivo. Basel: Karger, 1993;74-114.
104. [104] Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterizartion of angiogenin, an angiogenic protein from human colon carcinoma cells. Biochemistry 1985;24:5480-5486.
105. [105] Bicknell R, Vallee BL. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phosphorilase A2. Proc Natl Acad Sci USA 1989;86:1573-1577.
106. [106] Hansson HA, Brandsten C, Lossing C, Petrusen K Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol 1989;50:125-138.
107. [107] Nakao-Hayashi J, Ito H, Kanayasu T, Morita T, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1993;92:141-149.
108. [108] Pascual DW, Bost KL. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology 1990;71:52-56.
109. [109] Ben-Ezra D. Neovasculogenic ability of prostaglandins. growth factors and synthetic chemoattractants. Am J Ophthalmol 1978;86:455-461.
110. 1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-482.
111. 2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218.
112. [112] Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
113. [113] Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol 1994;9:807-843.
114. 2. Anat Rec 1994;238:68-76.
115. [115] Eisenstein R, Sorgente N, Soble L, Miller A, Kuettner K. The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 1973;73:765-774.
116. [116] Kuettner K, Soble L, Croxen R, Marczynska B, Hiti J, Harper E. Tumor cell collagenase and its inhibition by a cartilage-derived inhibitor. Science 1977;196:653-654.
117. [117] Langer R, Brem H, Falterman K, Klein M, Folkman J. Isolation of a cartilage factor which inhibits tumor neovascularization. Science 1976;193:70-72.
118. [118] Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-358.
119. [119] Folkman J. Diagnostic and therapeutic applications of angiogenesis research. CR Acad Sci 1993;316:914-918.
120. [120] Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145:365-374.
121. [121] Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 1994;14:1-4.
122. [122] O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by Lewis lung carcinoma. Cell 1994;79:315-328.
123. [123] D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
124. [124] Alesendro R, Spoonster J, Liotta L, Kohn E. Inhibition of angiogenesis by CAI, a novel inhibitor of signal transduction. Proc Am Assoc Cancer Res 1994;35:184.
125. [125] Beaffie GJ, Smyth JF. Early clinical studies of intraperitoneal matrix metalloproteinase hibitor BB 94 in patients with malignant ascites. Eur J Cancer 1995;31A:494
126. [126] Hawkins MJ, Clinical trials of antiangiogenic agents. Curr Opin Oncol 1995;7:90-93.